FDA Committees Vote on Opioid System Modulator for MDD Treatment

By November 05, 2018

In the meeting documents, the panel presented a scenario which illustrated their concerns regarding potentially complex drug interactions that may occur in the population for which the drug is intended.

FDA to Review Vraylar sNDA for Treatment of Bipolar Depression

By September 26, 2018

The sNDA included findings from the RGH-MD-53, RGH-MD-54, and RGH-MD-56 trials in which cariprazine was associated with greater improvement in change from baseline to week 6 on the Montgomery Asberg Depression Rating scale (MADRS) total score vs placebo in bipolar I patients.

Psilocybin Study Gets Green Light From FDA for Treatment-Resistant Depression

By August 22, 2018

The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.

Prevalence of Depression 4.4% Among Dads of Infants

July 25, 2018

Overall, 4.4% of the fathers who answered the PSF screened positive for depression, which was comparable to the 5.0% of mothers who screened positive. Fathers accounted for 11.7% of all parents who screened positive for depression.

Escitalopram Cuts MACE Risk in Depressed Patients With ACS

July 25, 2018

Higher risk of major adverse cardiac events with concurrent depression after acute coronary syndrome

FDA Fast-Tracks Novel Treatment for Major Depressive Disorder

By July 23, 2018

AGN-241751 is being developed in tandem with rapastinel, an investigational intravenous formulation of a novel NMDA receptor partial agonist, currently in Phase 3 development for MDD, as both a monotherapy and an adjunctive treatment.

Efavirenz Use and Depression, Suicidal Ideation: Is There a Link?

June 26, 2018

The researchers found that depression or suicidal ideation did not differ at baseline for patients ever exposed to efavirenz versus those never exposed to efavirenz and receiving nevirapine.

Older Age Tied to Poorer Course of Major Depressive Disorder

June 08, 2018

Results were slightly attenuated but remained mostly significant with adjustment for prognostic factors

ECT Effective for Treatment-Resistant Depression

May 15, 2018

ECT was projected to reduce time with uncontrolled depression from 50 to 33 to 37% of life-years over 4 years; greater improvements were seen when ECT was offered earlier.

Positive Results Announced for Esketamine in Treatment-Resistant Depression

By May 07, 2018

In both studies, the primary efficacy endpoint was change from baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.

Antidepressant Medications and Headache: Is There a Link?

By May 03, 2018

Compared to placebo, selective serotonin reuptake inhibitors (SSRIs) were associated with a significantly higher risk of headache (risk ratio [RR] 1.06, 95% CI: 1.00 to 1.13; P =.045).

Trintellix Labeling Updated With Data on Improved Processing Speed in MDD

By May 03, 2018

The approval was based on data from the 8-week, randomized, double-blind, placebo-controlled studies, FOCUS and CONNECT, which investigated the effect of Trintellix on various aspects of cognitive function among adults aged 18 to 65 years with depression.

NDA Submitted for Postpartum Depression Treatment Brexanolone

By April 23, 2018

Results in the 202B and 202C trials showed that brexanolone achieved the primary endpoint of mean reduction from baseline in the Hamilton Rating Scale for Depression.

FDA to Review Opioid System Modulator for Major Depressive Disorder

By April 16, 2018

ALKS 5461 consists of a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist.

<i>DSM-5</i>-Defined Major Depressive Disorder Highly Prevalent Among U.S. Adults

By March 21, 2018

To determine the prevalence of DSM-5 MDD as well as DSM-5 specifiers, the study authors conducted "in-person interviews with a representative sample of US noninstitutionalized civilian adults (≥18 years) (n = 36 309) who participated in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III)."

Progestin-Only Contraceptives and Depression: Is There a Link?

By February 28, 2018

Study quality was graded according to the United States Preventive Services Task Force and the Cochrane Risk of Bias Tools.

Serotonin Syndrome Risk Assessed With Concomitant Triptan, SSRI/SNRI Use

February 27, 2018

Researchers question FDA advisory warning on risk of concomitant use

CDC: Prevalence of Depression Examined Among U.S. Adults

February 14, 2018

Depression more common in women; lower among non-Hispanic Asians than other ethnic groups

NDA for Novel Major Depressive Disorder Treatment Submitted to FDA

By January 31, 2018

The NDA submission is based on a comprehensive clinical efficacy and safety package with data from more than 30 clinical trials.

Are Psychiatric Drugs Being Overprescribed in Children and Adolescents?

By January 30, 2018

"Our results show that, at a population level, prescriptions of stimulants and antidepressant medications for children and adolescents do not appear to be prescribed at rates higher than the known rates for psychiatric conditions they are designed to treat," said the study's lead author, Dr. Ryan Sultan.

Ketamine May Have 'Rapid' Effect on Suicidal Ideation in Depressed Patients

By December 15, 2017

The ketamine-treated patients demonstrated a clinically significant reduction in suicidal thoughts compared to the midazolam-treated patients within 24 hours (4.96 points greater reduction in SSI, 95% CI: 2.33, 7.59).

Sleep Deprivation: An Effective Antidepressant?

By September 21, 2017

Researchers from the Perelman School of Medicine at the University of Pennsylvania analyzed 66 studies to determine the antidepressant effects of sleep deprivation.

Recall: Antipsychotic Tablets Found in Antidepressant Bottle

By August 29, 2017

A Health Hazard Evaluation indicated a high risk to the patient ingesting the foreign tablet.

Sleep Duration Linked to Tx Response in Depressed Patients with Insomnia

By June 05, 2017

Findings from the study suggest that a shorter sleep duration may be a risk factor for refractory depression.

Dietary Supplement May Reduce Vulnerability to Postpartum Blues

March 14, 2017

Supplement designed to counter functions of elevated monoamine oxidase activity

Antidepressants Evaluated for Different Symptoms of Depression

February 28, 2017

Most drugs more effective for core emotional symptoms than for sleep, atypical symptoms

Antidepressants Often Prescribed for Unapproved Uses

February 23, 2017

Trazodone for insomnia most common off-label use for antidepressants

Do Pre-Existing Psychiatric Conditions Impact Opioid Use?

By December 29, 2016

Study authors reported evidence of greater opioid receipt among commercially insured patients with a wide range of psychiatric conditions.

Top 10 Most Costly Conditions in the U.S. Announced in New Report

By December 27, 2016

The highest amounts of spending were seen with these 10 conditions.

Treatment Combo Benefits Patients with Late-Life Depression

November 23, 2016

Characteristics associated with remission for AD PE include age 75 years and older, polypharmacy